The Development and Preliminary Application of the Chinese Version of the COVID-19 Vaccine Literacy Scale

Int J Environ Res Public Health. 2022 Oct 20;19(20):13601. doi: 10.3390/ijerph192013601.

Abstract

(1) Background: Vaccine literacy (VL) of the public is crucial to deal with anti-vaccination rhetoric. This study aims to (1) develop a Chinese COVID-19 Vaccine Literacy Scale and examine the factor structure and psychometric characteristics, and (2) explore the association between COVID-19 VL and sociodemographic characteristics and other variables; (2) Methods: An online cross-sectional survey was conducted among 362 Chinese residents from 23 May 2022 to 31 May 2022 using snowball sampling; (3) Results: Exploratory and confirmatory factor analysis indicated that the scale of 15 items, consisting of three factors, functional, interactive and critical vaccine literacy, explained 63.3% of the total variance. Cronbach's α coefficient was 0.885 for the overall scale: 0.838, 0.891, and 0.857 for three subscales, respectively. The results showed a medium level of vaccine literacy (M = 3.71, SD = 0.72) and significant differences among functional, interactive, and critical vaccine literacy (p < 0.001). The level of vaccine literacy grew with the level of education (p < 0.001) and age (p = 0.049). Men, participants who were single, or those living in rural areas had a lower level of vaccine literacy; (4) Conclusions: The Chinese COVID-19 VL Scale has adequate validity and reliability for assessing vaccine literacy among Chinese residents. A deep understanding of the factors that affect vaccine literacy is needed.

Keywords: COVID-19; Chinese; general public; scale; vaccination; vaccine literacy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19 Vaccines
  • COVID-19* / epidemiology
  • COVID-19* / prevention & control
  • China
  • Cross-Sectional Studies
  • Health Literacy*
  • Humans
  • Male
  • Psychometrics / methods
  • Reproducibility of Results
  • Surveys and Questionnaires

Substances

  • COVID-19 Vaccines